According to WHO, pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. The major aim of pharmacovigilance systems is early detection of unknown, drug safety problems, detection of increases in frequency, identification of risk factors quantifying risks, preventing patients from being affected unnecessarily.


With the ultimate objective of patient safety first, S A A F continuously complies with Good Pharmacovigilance Practice (GPP), to assure standards and innovations in the collection, management, analysis, and use of medication safety information. We share the risks and benefits with the entire team, both internal and our external partners, through structured governance and communications at every level, and endeavor to meet the evolving global and local regulatory requirements.


At S A A F, reducing error and harm from medicines through safe and quality use is an important element of our work and is helping us to achieve our objective of leading and coordinating safety and quality improvements in healthcare.

With the aim to enhance patient care and patient safety in relation to the use of medicines we work to:

Promote discussion and communication about safe medication use, medication errors, side effects, and error-prevention strategies among health care providers and the public;
Educate consumers and patients regarding strategies to prevent medication errors for both prescription and non-prescription medications;
Develop and broadly disseminate local and global recommendations and other work products related to reporting, understanding, and prevention of medication safety;
Collaborate with other interested stakeholders to address special topics related to medication errors and patient safety initiatives. Educate healthcare professionals about the causes of medication errors and strategies for prevention.


At S A A F we commit to:

Be vigilant about the safety profile of our products while encouraging their safe and effective use

Proactively assess and manage drug safety throughout the life cycle of our products

Develop scientific risk management strategies and contribute to operational excellence in full compliance of local and global pharmacovigilance systems

In case you come across any adverse events related to our products, please feel free to connect with S A A F’s Pharmacovigilance (PV) team.

Contact :

Dr. Sumaira

Phone : 00971-55-6871954, 00971-55-2903499
Email :,